Ranger DCB
Peripheral Artery Disease
Key Facts
About Boston Scientific
Boston Scientific is a diversified medical device leader with a mission to advance science for life by delivering innovative, minimally invasive solutions. The company has achieved sustained growth through strategic diversification beyond its cardiovascular roots into high-growth areas like neuromodulation and endoscopy, supported by a robust R&D engine and strategic acquisitions. Its strategy focuses on addressing unmet clinical needs with category-leading technologies, driving global expansion, and improving patient outcomes while delivering shareholder value.
View full company profileTherapeutic Areas
Other Peripheral Artery Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Peripheral Artery Disease Program | Elixir Medical | Pre-clinical |
| Aperta NSE™ PTA | Nipro Medical | Commercial |
| JTV-263 | Akros Pharma | Phase1 |
| Luminor DCB | iVascularU | Post-Market |
| iVolution pro Stent | iVascularU | Post-Market |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |